S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Nobel Prize Winner's Premonition About Nuclear Energy Comes True (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
The Critical Minerals Race: U.S. v China (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
The Critical Minerals Race: U.S. v China (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Closing prices for crude oil, gold and other commodities
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Nobel Prize Winner's Premonition About Nuclear Energy Comes True (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
The Critical Minerals Race: U.S. v China (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
The Critical Minerals Race: U.S. v China (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Closing prices for crude oil, gold and other commodities
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Nobel Prize Winner's Premonition About Nuclear Energy Comes True (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
The Critical Minerals Race: U.S. v China (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
The Critical Minerals Race: U.S. v China (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Closing prices for crude oil, gold and other commodities
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Nobel Prize Winner's Premonition About Nuclear Energy Comes True (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
The Critical Minerals Race: U.S. v China (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
The Critical Minerals Race: U.S. v China (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Closing prices for crude oil, gold and other commodities
NYSE:ZTS

Zoetis - ZTS Stock Forecast, Price & News

$153.68
+3.43 (+2.28%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$149.20
$154.35
50-Day Range
$131.14
$157.42
52-Week Range
$124.15
$249.27
Volume
2.25 million shs
Average Volume
2.29 million shs
Market Capitalization
$71.63 billion
P/E Ratio
35.09
Dividend Yield
0.87%
Price Target
$215.17

Zoetis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
40.0% Upside
$215.17 Price Target
Short Interest
Healthy
0.87% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.96mentions of Zoetis in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
10.27%
From $4.87 to $5.37 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.82 out of 5 stars

Medical Sector

43rd out of 1,022 stocks

Pharmaceutical Preparations Industry

18th out of 499 stocks

ZTS stock logo

About Zoetis (NYSE:ZTS) Stock

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Stock News Headlines

Calculating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
The Critical Minerals Race: U.S. v China
The U.S. is dangerously lacking in critical minerals such as cobalt, lithium, and rare earths needed to maintain our national security. China is aggressively locking up mines and production. But the U.S. is about to strike back with a forceful plan of action to increase domestic production.
Calculating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
The Critical Minerals Race: U.S. v China
The U.S. is dangerously lacking in critical minerals such as cobalt, lithium, and rare earths needed to maintain our national security. China is aggressively locking up mines and production. But the U.S. is about to strike back with a forceful plan of action to increase domestic production.
Zoetis and 5 More Healthcare Stocks With Room to Climb
Zoetis Announces Pricing of $1.35 Billion of Senior Notes
Zoetis Inc.'s (NYSE:ZTS) Share Price Not Quite Adding Up
Why Zoetis Stock Was Falling Today
Zoetis (ZTS) Q3 Earnings and Revenues Miss Estimates
Zoetis (ZTS) Q3 2022 Earnings Call Transcript
Zoetis Announces Third Quarter 2022 Results
Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Company Calendar

Ex-Dividend for 12/1 Dividend
10/31/2022
Last Earnings
11/03/2022
Dividend Payable
12/01/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/21/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
98978V10
Employees
12,100
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$215.17
High Stock Price Forecast
$248.00
Low Stock Price Forecast
$180.00
Forecasted Upside/Downside
+40.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$2.04 billion
Pretax Margin
32.10%

Debt

Sales & Book Value

Annual Sales
$7.78 billion
Cash Flow
$5.81 per share
Book Value
$9.60 per share

Miscellaneous

Free Float
465,513,000
Market Cap
$71.63 billion
Optionable
Optionable
Beta
0.72

Social Links


Key Executives

  • Ms. Kristin C. PeckMs. Kristin C. Peck (Age 51)
    CEO & Director
    Comp: $3.86M
  • Mr. Wetteny N. JosephMr. Wetteny N. Joseph (Age 50)
    Exec. VP & CFO
    Comp: $2.91M
  • Ms. Heidi C. ChenMs. Heidi C. Chen (Age 55)
    Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics
    Comp: $1.39M
  • Mr. Glenn C. DavidMr. Glenn C. David (Age 50)
    Exec. VP & Group Pres of U.S. Operations, Global Diagnostics and BioDevices
    Comp: $1.9M
  • Ms. Roxanne LaganoMs. Roxanne Lagano (Age 57)
    Exec. VP and Chief HR Officer & Global Operations
  • Ms. Wafaa Mamilli (Age 55)
    EVP, Chief Digital & Tech. Officer, Group Pres for China, Brazil and Preci. Animal Health
  • Mr. Steven Frank
    VP of Investor Relations
  • Mr. William Price
    VP & Chief Communications Officer
  • Dr. Robert J. Polzer Ph.D. (Age 53)
    Exec. VP and Pres of R&D
  • Ms. Jeannette Ferran Astorga (Age 47)
    Exec. VP of Corp. Affairs & Communications and Chief Sustainability Officer













ZTS Stock - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price forecast for 2023?

7 analysts have issued twelve-month target prices for Zoetis' stock. Their ZTS share price forecasts range from $180.00 to $248.00. On average, they expect the company's stock price to reach $215.17 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2022?

Zoetis' stock was trading at $244.03 at the start of the year. Since then, ZTS shares have decreased by 37.0% and is now trading at $153.68.
View the best growth stocks for 2022 here
.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest in October. As of October 31st, there was short interest totaling 4,260,000 shares, an increase of 37.4% from the October 15th total of 3,100,000 shares. Based on an average daily trading volume, of 2,010,000 shares, the short-interest ratio is presently 2.1 days. Approximately 0.9% of the shares of the stock are sold short.
View Zoetis' Short Interest
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our ZTS earnings forecast
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings results on Thursday, November, 3rd. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.24 by $0.03. The business earned $2 billion during the quarter, compared to the consensus estimate of $2.08 billion. Zoetis had a net margin of 25.82% and a trailing twelve-month return on equity of 48.41%. The firm's quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.25 earnings per share.
Read the conference call transcript
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Thursday, October 13th. Stockholders of record on Tuesday, November 1st will be given a dividend of $0.325 per share on Thursday, December 1st. This represents a $1.30 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Monday, October 31st.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.30 per share and currently has a dividend yield of 0.87%. The company has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 29.68%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 24.21% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of $4.83-$4.90 for the period, compared to the consensus earnings per share estimate of $5.00. The company issued revenue guidance of $8.00 billion-$8.07 billion, compared to the consensus revenue estimate of $8.26 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.84%), Vanguard Group Inc. (7.84%), State Street Corp (4.25%), Alliancebernstein L.P. (4.10%), Price T Rowe Associates Inc. MD (2.23%) and Nuveen Asset Management LLC (1.30%). Insiders that own company stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $153.68.

How much money does Zoetis make?

Zoetis (NYSE:ZTS) has a market capitalization of $71.63 billion and generates $7.78 billion in revenue each year. The company earns $2.04 billion in net income (profit) each year or $4.38 on an earnings per share basis.

How many employees does Zoetis have?

The company employs 12,100 workers across the globe.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Holding Limited, Abaxis Europe GmbH, Abaxis Holding GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma (Bermuda) LLC, Alpharma (Luxembourg) S.A.R.L. y Compania Limitada, Alpharma (Luxembourg) S.àr.l., Alpharma Animal Health (Hong Kong) Co. Limited, Alpharma Animal Health Company, Alpharma Euro Holdings LLC, Alpharma Holdings (Barbados) SRL, Alpharma LLC, Alpharma do Brasil Ltda., Bovigen, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Mikjan Corporation, NVIP Pty Ltd, Nexvet, Nexvet Australia Pty Ltd, Nordic Fish Tech AB, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PHARMAQ LTD, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS Technika SpA, Pharmaq Analytiq AS, Pharmaq CA Panama Inc., Pharmaq Fishteq AS, Pharmaq Holding AS, Pharmaq Settvac AS, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Platinum Performance, Platinum Performance Inc., Platinum Performance Nutrition Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics LLC, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis (Thailand) Limited, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark Aps, Zoetis Deutschland GmbH, Zoetis Egypt Import LLC, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management (Shanghai) Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis International Services, Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Lab Holdings LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa (Pty) Ltd., Zoetis Spain S.L., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Taiwan Limited, Zoetis Treasury Center BVBA, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for the company is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at steve.frank@zoetis.com, or via fax at 302-655-5049.

This page (NYSE:ZTS) was last updated on 12/9/2022 by MarketBeat.com Staff